About Boule Diagnostics

Boule Diagnostics AB (publ) is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies to which it offers complete systems for blood diagnostics (hematology) in both the human and veterinary areas. Boule has strong positions in important emerging markets such as in Asia and in recent years has improved its position in the fast-growing veterinary market. Operations are conducted through operating subsidiaries in Sweden, the United States, Mexico and Russia. The Group reported net sales of SEK 548 million in 2022 and has more than 200 employees. Sales are conducted globally, predominantly through the company's 200 or so distributors in over 100 countries, supported by Boule's own local sales and service personnel. Boule has been listed on Nasdaq Stockholm since 2011.



Other information

Calendar

Interim report Q1 2023	May 3, 2023
2023 Annual General Meeting	May 4, 2023
Interim report Q2 2023	July 24, 2023
Interim report Q3 2023	November 9, 2023

Presentation of the year-end report
CEO Jesper Söderqvist and CFO Annette Colin will present and comment on the year-end report through Teams. After the presentation, there will be time for questions.
The presentation will be held in English. Time: 10.00, 2 February, 2023

Please follow this link to participate!



Jesper Söderqvist
President and CEO
+46 (0)70-689 05 90
jesper.soderqvist@boule.com



Annette Colin
CFO
+46 (0)70-319 06 76
annette.colin@boule.com

This information is information that Boule Diagnostics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:30 CET on February 2, 2023.